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Abstract
Background: The purpose of this trial was to test if the Norfolk Diabetes Prevention Study (NDPS) lifestyle
intervention, recently shown to reduce the incidence of type 2 diabetes in high-risk groups, also improved
glycaemic control in people with newly diagnosed screen-detected type 2 diabetes.
Methods: We screened 12,778 participants at high risk of type 2 diabetes using a fasting plasma glucose and
glycosylated haemoglobin (HbA1c). People with screen-detected type 2 diabetes were randomised in a parallel,
three-arm, controlled trial with up to 46 months of follow-up, with a control arm (CON), a group-based lifestyle
intervention of 6 core and up to 15 maintenance sessions (INT), or the same intervention with additional support
from volunteers with type 2 diabetes trained to co-deliver the lifestyle intervention (INT-DPM). The pre-specified
primary end point was mean HbA1c compared between groups at 12 months.
Results: We randomised 432 participants (CON 149; INT 142; INT-DPM 141) with a mean (SD) age of 63.5 (10.0) years,
body mass index (BMI) of 32.4 (6.4) kg/m2, and HbA1c of 52.5 (10.2) mmol/mol. The primary outcome of mean HbA1c at
12months (CON 48.5 (9.1) mmol/mol, INT 46.5 (8.1) mmol/mol, and INT-DPM 45.6 (6.0) mmol/mol) was significantly lower
in the INT-DPM arm compared to CON (adjusted difference −2.57mmol/mol; 95% CI −4.5, −0.6; p = 0.007) but not
significantly different between the INT-DPM and INT arms (−0.55mmol/mol; 95% CI −2.46, 1.35; p = 0.57), or INT vs CON
arms (−2.14mmol/mol; 95% CI −4.33, 0.05; p = 0.07). Subgroup analyses showed the intervention had greater effect in
participants < 65 years old (difference in mean HbA1c compared to CON −4.76mmol/mol; 95% CI −7.75, −1.78mmol/
mol) than in older participants (−0.46mmol/mol; 95% CI −2.67, 1.75; interaction p = 0.02). This effect was most significant
in the INT-DPM arm (−6.01mmol/mol; 95% CI −9.56, −2.46 age < 65 years old and −0.22mmol/mol; 95% CI −2.7, 2.25;
aged > 65 years old; p = 0.007). The use of oral hypoglycaemic medication was associated with a significantly lower mean
HbA1c but only within the INT-DPM arm compared to CON (−7.0 mmol/mol; 95% CI −11.5, −2.5; p = 0.003).
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Conclusion: The NDPS lifestyle intervention significantly improved glycaemic control after 12months in people with
screen-detected type 2 diabetes when supported by trained peer mentors with type 2 diabetes, particularly those
receiving oral hypoglycaemics and those under 65 years old. The effect size was modest, however, and not sustained at
24months.
Trial registration: ISRCTN34805606. Retrospectively registered 14.4.16
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Introduction
Nearly half a billion people are living with diabetes
worldwide, with more than 4 million in the UK [1–3],
and we need effective lifestyle modification interventions
to prevent type 2 diabetes and improve clinical out-
comes [4–11]. In the UK, national policy is that people
in a ‘high risk of Type 2 diabetes’ glycaemic category
should be offered a diet and lifestyle intervention [4]. In
parallel, UK policy recommends people with newly diag-
nosed type 2 diabetes should have access to structured
education, with self-management advice, an emphasis on
diet and lifestyle modification, delivered by trained edu-
cators, and with a theory-driven, quality-assured, and
evidence-based structured curriculum [7]. A lifestyle
intervention that was found to be effective in both type
2 diabetes prevention and in improving glycaemic con-
trol in people with type 2 diabetes would be an attractive
choice for clinicians and policy makers. This seems in-
tuitively likely, as the key elements of preventive lifestyle
interventions (increased physical activity, dietary modifi-
cation, and weight loss targets) have modest but statisti-
cally significant effects on glycaemic control in type 2
diabetes [8–11]. However, the few lifestyle interventions
shown to reduce the risk of type 2 diabetes in current
high risk of diabetes glycaemic categories have not been
tested as an intervention in people with type 2 diabetes.
The increasing clinical workload in type 2 diabetes
management has driven a search for better and less ex-
pensive workforce models, including the use of lay vol-
unteers. Small or observational studies have commonly
shown benefits from such support in people with type 2
diabetes [12–18]. Shared life experience may help to
support the development of motivation for lifestyle
change, and ‘modelling’ of behaviours by credible others
is a recognised behaviour change technique [19, 20].
People with type 2 diabetes themselves are an obvious
choice as true peer supporters since they are demo-
graphically similar to the target group, share a common
experience of being diabetes aware, and face the same
lifestyle challenges. However, the value of using lay
people with type 2 diabetes themselves to work in this
role alongside health care professionals has not been
tested in a large clinical trial.
We recently reported results from the Norfolk Dia-
betes Prevention Study (NDPS), a clinical trial testing
the effectiveness of a group-delivered diet and lifestyle
intervention, with or without additional support from
trained peer volunteers with type 2 diabetes themselves,
to prevent type 2 diabetes in high-risk groups [21]. The
intervention was effective in reducing the risk of incident
type 2 diabetes, by 40–48% over 2 years [21]. The NDPS
screening programme also identified many people with a
new diagnosis of type 2 diabetes [21–24]. We hypothe-
sised that the NDPS lifestyle intervention would improve




NDPS was a research programme conducted between
2011 and 2018 in the East of England (UK National In-
stitute for Health Research NIHR RP PG 0109 –10013).
The programme protocol, baseline characteristics of the
screened population, and results from the main preven-
tion trial are published [21–24], and the initial protocol
and final statistical analysis plan (SAP) are available as
Additional files 1 and 2. The NDPS screening programme
[21–24] was intended to detect people with a ‘high risk of
Type 2 diabetes’ glycaemic category for entry into a pre-
vention trial, but also detected people with newly diag-
nosed, ‘screen detected’ type 2 diabetes. The parallel,
three-arm randomised controlled trial reported here ran
alongside the prevention trial and examined the effects of
the NDPS lifestyle intervention, with or without support
from trained peer volunteers with type 2 diabetes (DPM)
[21–24] on glycaemic control (HbA1c) in people with
screen-detected type 2 diabetes, with pre-specified end
points at 12 and 24months [24]. The CONSORT checklist
is available as Additional file 3.
Recruitment
To identify high-risk participants eligible for screening,
we contacted 194 primary care practices in the East of
England and 135 (70%) collaborated. Based on searches
of computerised patient databases in each practice, we
invited all individuals without known diabetes in these
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practices who (a) were aged ≥ 40 years and with a re-
corded body mass index (BMI) ≥ 30 kg/m2 or (b) were
aged ≥ 40 years and with a BMI ≥ 25 kg/m2 and a re-
corded first degree family history of type 2 diabetes, or a
history of coronary artery disease, or gestational diabetes
or (c) were recorded in any previous high risk of type 2
diabetes glycaemic category [24].
Screening
Potential participants were initially screened with fasting
plasma glucose and venous HbA1c measurements, and
biometric and medical history data were collected [24]
in 8 screening sites across the East of England. Partici-
pants with an eligible glycaemic category on initial test-
ing had repeated testing a median 40 days (interquartile
range 27–69 days) later [21–24]. Trial randomisation
was offered if participants met the inclusion criteria
described below. The first screening appointment was
August 22, 2011, and last March 24, 2017.
Inclusion criteria
Eligibility for randomisation into this trial was initially
for participants with fasting plasma glucose ≥ 7.0 mmol/l
on paired baseline samples. In light of international
changes in diabetes diagnostic criteria during the
programme and UK national policy changes [4, 25–28],
we also then enrolled screened participants with paired
HbA1c ≥ 48mmol/mol for the diagnosis of type 2 dia-
betes from May 2014 [21–24]. In the initial years of this
programme (end 2011–2013), there was still uncertainty
about the clinical adoption of HbA1c as a test for the
diagnosis of type 2 diabetes in normal UK practice, com-
pared to data obtained during a standard 75-g oral glu-
cose tolerance test (OGTT) [28, 29]. To exclude an
OGTT-based diagnosis of type 2 diabetes (paired 2-h
plasma glucose > 11.1 mmol/l) and incorrect randomisa-
tion into the NDPS diabetes prevention trial [21, 24], we
undertook an OGTT in higher risk screened participants
(fasting plasma glucose ≥ 6.1–< 7.0 mmol/l and HbA1c >
42mmol/mol) and recruited into the trial reported here
those with paired OGTT 2-h glucose values of both >
11.1 mmol/mol. Participants who declined a repeat
OGTT after an initial diagnostic value were also offered
randomisation into this trial if they had paired baseline
HbA1c ≥ 48mmol/mol [24–29]. Participants with a sin-
gle abnormal OGTT were also accepted if they had ex-
treme or symptomatic hyperglycaemia.
Ethical issues
Ethical approval was obtained from the National Re-
search Ethics Service (NRES), Essex 1 Research Ethics
Committee (10/H0301/55; January 13, 2011), and all
participants gave written informed consent. Participants
with newly diagnosed type 2 diabetes were informed of
their diagnosis and offered discussion with the study
team and CI. Each participants’ primary care clinician
was informed of the diagnosis, and normal diabetes care
and management was provided outside the trial protocol
by their usual clinician.
Randomisation and consent
We randomised participants in parallel with the screen-
ing programme using a rolling recruitment approach
with screening and randomisation continuing from Au-
gust 2011 until 6.4.2017. This allowed each participant
to reach a 12months minimum and 46months max-
imum follow-up within the trial. Randomisation was
conducted automatically using a dedicated algorithm in
the trial data management system. The randomisation
mechanism consisted of a pre-prepared random list of
codes (for the intervention and control groups) stored in
the trial database, and randomisation to groups was in a
1:1:1 ratio [24]. Randomisation enrollment was under-
taken by NDPS diabetes prevention facilitators (DPF).
Interventions
The NDPS intervention is described in detail elsewhere
[21, 24]. Eligible participants were randomised into a
control arm (CON) who received no trial intervention,
an intervention arm (INT) who received the lifestyle
intervention (INT), or an intervention arm who received
the same intervention, but with additional telephone
support from peer volunteer diabetes prevention men-
tors (INT-DPM).
Control (CON) group The CON arm participants
attended a single, 2-h, group-based session delivered by
a DPF [24]. Discussions included a presentation and
written information on type 2 diabetes at diagnosis, and
the impact of lifestyle modification, in line with then
current local NHS clinical policy. CON arm participants
did not then receive any additional in trial lifestyle modi-
fication advice.
Intervention (INT) group The intervention comprised
six, 2-h educational group sessions for the first 12 weeks,
followed by up to 15 maintenance sessions 8 weeks apart
from month 4 onwards. Maintenance sessions were 2.5 h
in duration and included 90min of discussion-based ac-
tivities to review progress and action plans and discuss
key topics relating to lifestyle change and maintenance.
Every maintenance session also included a 50-min su-
pervised physical activity/muscle-strengthening exercise
session. The maximum possible session contact time per
participant was up to 49.5 h. Sessions contained no more
than 15 participants each. Participant groups included
people with a ‘high risk of Type 2 diabetes’ glycaemic
category in the prevention trial [21, 24] as well as people
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with screen-detected type 2 diabetes, and participants
were not informed of each other’s glycaemic category.
The INT arm intervention was delivered by DPF alone.
Intervention and mentor (INT-DPM) group Partici-
pants randomised to the INT-DPM arm received the
same intervention as the INT group as described above
(six ‘core’ education sessions with a maximum number
of 15 maintenance sessions) but in addition received up
to 18 individual motivational telephone calls scheduled
between intervention sessions [21, 24]. DPMs were each
assigned up to seven participants and telephone contacts
were monthly for the first 3 months and then every 2
months. During these contacts, the DPM and partici-
pants discussed progress, goal achievement, action plan-
ning, and barriers to coping. INT-DPM participants
therefore received a contact from the study at least every
4 weeks. The INT-DPM arm intervention was delivered
jointly by DPF and trained volunteers with type 2 dia-
betes themselves (DPM) [22, 24]. DPMs were from a
range of professional backgrounds and trained to co-
deliver the lifestyle intervention [22].
The intervention was based on the Process Model for
Lifestyle Behaviour Change [30, 31] and aimed to sup-
port the maintenance of changes in physical activity and
diet, using patient-centred counselling techniques to en-
courage decision-making about behaviour change, in-
crease motivation to change, engage social support, and
aid individually tailored goal setting, action planning,
self-monitoring, and support problem solving [21–24].
Behaviour change targets were set by participants, who
were encouraged to think about (and presented with the
health benefits of) achieving 7% weight loss if BMI was
> 30 kg/m2, achieving 150 min per week of moderate-
intensity physical activity over 5 days or more, undertak-
ing 2–3 sessions of muscle-strengthening exercise per
week, and reducing intake of total and saturated fat. Par-
ticipants who had a BMI under 30 kg/m2 were not given
a suggested weight loss target but were advised to work
towards achieving a BMI within a healthy range and that
any movement towards that range would be beneficial.
Participants in the two intervention groups were add-
itionally given a pedometer as a motivational tool to en-
courage an increase in activity. These data were not
collected for analysis but allowed the participants to
monitor and self-regulate their exercise behaviour. Ped-
ometer data were discussed as part of participants’ pro-
gress reviews within the intervention sessions and DPM
telephone calls.
All trial participants received normal clinical diabetes
care from their existing primary care team in line with
normal clinical practice and uniform glycaemic targets
[32], and none received a structured lifestyle interven-
tion from other sources in parallel with the NDPS
intervention. Intervention fidelity was assessed by audio-
recording all intervention sessions and a scoring check-
list was applied to a sample of these sessions by inde-
pendent observers. DPFs were required to complete a
checklist at the end of every session reporting on the
perceived levels of fidelity reached [24]. The completion
rate for the DPF-completed checklists was 91.7% and
these data will be reported separately.
DPM training and characteristics
A full description of the DPM training and characteris-
tics has been published [22]. We invited 9951 people
with type 2 diabetes to become DPM. Four hundred
twenty-seven (4.3%) individuals responded, 356 (83.3%)
were interviewed by phone, and 131 (36.8%) were inter-
viewed face to face. One hundred four (79%) were
appointed to the role (mean age 62 years, 55% [n = 57]
male), volunteering for a total of 2895 months, and made
6879 telephone calls to randomised participants in the
full NDPS programme [24]. Seventy-five (72%) DPM
volunteered for at least 6 months and fifty-four (52%)
for at least 1 year. The study-specific training
programme was designed as a standardised training
programme to allow for exact replication in future co-
horts. Group training seminars were delivered over 7
weeks (one per week) allowing time for self-reflection
and reading between seminars. Each seminar lasted 2.5
h. The training had two aims: to provide up-to-date in-
formation on physical activity, diet, pre-diabetes, and
lifestyle-related areas and secondly to undertake practice
role play work to allow for the development of the key
skills required for the role.
Outcome measures
The primary pre-specified outcome was mean HbA1c at
12 months, and pre-specified secondary outcomes in-
cluded biometric, biochemical, behavioural, and quality
of life measures, which are described elsewhere [24].
The Quality and Outcomes Framework (QOF) is a UK
primary care incentive scheme for many conditions, and
for diabetes, the main QOF metric is simply the percent-
age of people in a primary care diabetes population
achieving agreed target glycaemic levels [32]. We also re-
port QOF attainment at baseline and at 12 months by
trial arm as a primary end point. Weight, body mass
index (BMI), body fat mass (kg), and visceral fat were
measured using a Tanita body fat composition analyser
(TANITA - Hoogoorddreef, 1101 BE, Amsterdam, The
Netherlands; Model BC-420 MA), with a possible vis-
ceral fat score of 1–59, with a rating between 1 and 12
indicating a healthy level of visceral fat and 12–59 indi-
cating excessive level of visceral fat. Fasting plasma glu-
cose was measured using the hexokinase/G-6-PDH
method (Architect c8000: Abbott, Maidenhead, UK).
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HbA1c was measured using Affinity high-performance li-
quid chromatography (Hb9210: Menarini Diagnostics Ltd.,
Wokingham, UK). Fasting plasma insulin was measured on
the Siemens Immulite 2000 XPI (Siemens Healthcare Ltd,
Frimley, Camberley, Surrey; GU16 8QD), and homeostasis
model assessment (HOMA) of insulin sensitivity and beta
cell function were calculated [33]. Physical activity was self-
reported using the short form International Physical Activ-
ity Questionnaire (IPAQ) [34, 35] which gathers informa-
tion on the intensity (vigorous, moderate, or light) and
duration of a range of activities engaged in over the course
of the last week and also the amount of sedentary activity
measured in hours each day. Physical activity outputs were
reported in categories (low, moderate, high) and converted
to Metabolic Equivalents (METS) to express the intensity
of physical activity [34, 35]. Resistance activity was assessed
via a study-specific two-item questionnaire measuring the
type of resistance activity, the number of minutes per day,
and the number of days per week the participant engaged
in resistance activity. This questionnaire was measured
alongside the IPAQ. In the NDPS programme, a small
number of accelerometers were used between all rando-
mised participants in the main prevention trial (24) and this
trial. If an accelerometer was available for assignment, it
was provided to the next attending participant but the data
was only measured in a very small subsample of partici-
pants in this trial. This use of accelerometers in only a sub-
set of participants is specified in protocol (Additional File;
Protocol p41), but there are insufficient data from this small
accelerometry dataset to be of value, and are nor reported
here. Dietary behaviours related to fat and fibre intake were
assessed using a Diet Behaviour Questionnaire (DBQ)
adapted from an existing dietary questionnaire [36]. Well-
being was assessed by the WBQ-12 questionnaire, which
captures general well-being, including negative well-being,
energy, and positive well-being [37]. Health-related quality
of life was measured using the EuroQol EQ-5D [38, 39].
Diabetes quality of life was assessed using the Audit of
Diabetes-Dependent Quality of Life (ADDQol) question-
naire [39]. Measures of deprivation for each participant
were derived from their postcode and published indices of
deprivation [40]. The Diabetes Treatment Satisfaction
Questionnaire (DTSQ) [41] and diabetes management self-
efficacy scale (DMSES) [42] were used at follow-up time
points [24]. Participant medication use was ascertained
using data collected from a health resources use (HRU)
questionnaire, the trial case report form (CRF) data collec-
tion, and direct interview with participants by programme
staff at trial end to ascertain medication use at 12months.
Health economic analysis
A within-trial analysis estimated the cost-effectiveness of
the intervention (with and without DPM), compared to
usual care. To estimate costs (from a UK National
Health Service (NHS) perspective at 2016-2017 prices),
those who delivered the intervention recorded the re-
source use (time inputs) associated with the training,
education, and maintenance sessions, plus ongoing
supervision/support. Additionally, all participants were
asked to complete a self-report health service use ques-
tionnaire at baseline, 6-, 12-, and 24-month time points
[43]. Unit costs were assigned to each item of resource
use [43–45]. Additional DPM costs included training, a
telephone charge cost for each call, and DPM supervi-
sion, as well as a single honorarium payment of £350 for
each DPM. Effectiveness was estimated based on the
quality-adjusted life year (QALY) scores which were de-
rived from the EQ-5D-3L [45–47]. Incremental costs per
QALY were estimated over a 24-month follow-up
period, where costs and QALYs incurred after 12
months were discounted at 3.5% and multiple imput-
ation was used to estimate missing data [48]. Bivariate
regression analysis [49, 50] was undertaken and the in-
cremental cost-effectiveness ratio (ICER: mean incre-
mental cost/mean incremental effect) was estimated.
Statistical analysis and power estimates
The primary statistical analysis compared mean HbA1c
between the three trial arms using observed data. The
comparison was based on a linear regression model with
the arm as a fixed effect and adjusted for the baseline
value of the outcome. Other continuous outcomes were
assessed using the same approach. Binary outcomes were
compared using a logistic regression using the same ap-
proach. Pre-specified subgroup analyses were conducted
by including an interaction between the arm and the
subgroup in the regression models separately for sex,
age (< 65 vs ≥ 65), deprivation quartile, and BMI quar-
tile. A post hoc analysis of oral hypoglycaemic use, or no
reported oral hypoglycaemic use on the primary out-
come by trial arm was also undertaken. The sensitivity
of the results to missing data was assessed by multiply
imputing the missing outcomes for individuals using it-
erative chain equations. Missing data were assumed to
be missing at random due to the reasons provided for
drop-out, and that for the 24-month data, the main rea-
son for missingness was that the rolling recruitment
strategy meant randomised participants would reach a
minimum of 12 months but would not reach 24months
by programme end. In order to control for type-1 error,
we pre-specified a restricted analysis to only the 12- and
24-month follow-up data, with 12-month data (365 days
from randomisation ± 45 days) selected as the primary
end point. We pre-specified this final statistical analysis
plan (SAP) in agreement with programme independent
data monitoring and ethics committee (DMEC). This
SAP (12.10.18) is available as an Additional material file,
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and antedated programme completion, database lock-
down, or any analyses.
Four between-arm comparisons were made: INT-DPM
vs INT, INT vs CON, INT-DPM vs CON, and INT
combined with INT-DPM vs CON (a post hoc analysis).
Within-arm analyses examined the association between
intervention exposure (dose) and outcomes with dose
defined as follows: For the INT group, the ‘dose of inter-
vention’ attained was defined as LOW (less than 30% at-
tendance at sessions), MODERATE (between 30 and
59% attendance), and HIGH (at least 60% attendance at
sessions). For the INT-DPM group, these doses were de-
fined as LOW (less than 30% attendance at sessions re-
gardless of calls connected OR less than 30% of calls
connected regardless of attendance at sessions), MOD-
ERATE (between 30 and 59% attendance at sessions and
more than 30% of calls connected or between 30 and
59% of calls connected and more than 30% attendance
at sessions), and HIGH (at least 60% attendance at ses-
sions AND at least 60% of calls connected). Linear re-
gression models were used for the dose-response
analysis within each intervention arm. The factors ad-
justed for were based on a backward elimination algo-
rithm starting with all baseline measures, retaining those
that were significant at the 5% level. The baseline mea-
sures (Table 1) were considered to be potential con-
founders of the associations between intervention dose
and outcome and included sociodemographic, behav-
ioural, biometric, and generic health variables. These
variables were considered as potential confounders be-
cause they could either directly influence both interven-
tion uptake and change in HbA1c or glucose (through
mechanisms other than the intervention) or be indirect
indicators of behavioural and physical health at baseline
that could also influence intervention uptake and out-
comes. The statistical analysis plan (SAP), sample size
estimates, and initial power calculations have been de-
scribed [24; Additional material File]. The initial power
estimates were based on 90% power to detect a mean
difference in HbA1c of 0.5% (DCCT aligned HbA1c;
2010) between trial arms, with an initial sample size of n
= 100 per group.
Results
Participant recruitment and characteristics
We invited 141,973 people at increased risk of type 2
diabetes to participate in the screening programme, of
whom 12,778 (9.0%) were screened. We detected 571
people with screen-detected type 2 diabetes (4.5%), of
whom 432 (75.4%) consented to randomisation into trial
arms: CON: n = 149, INT: n = 142, and INT-DPM: n =
141. Baseline characteristics (Table 1) and flow through
trial, including loss to follow-up data, and the reasons
for participants declining randomisation are shown
(Fig. 1).
Of the 432 randomised participants, 74 (17.1%) were
diagnosed on the basis of paired fasting plasma glucose
measurements ≥ 7.0 mmol/l alone, 150 (34.7%) with
paired HbA1c ≥ 48 mmol/mol alone, and 145 (33.6%)
met both HbA1c and fasting glucose diagnostic criteria.
In the early years of this programme, we randomised 29
(6.7%) with paired baseline 2-h OGTT values > 11.1
mmol/l, and 31 (7.3%) with a single OGTT > 11.1 mmol/
l (28 with paired HbA1c > 48 mmol/mol and three with
symptomatic hyperglycaemia), and 3 (0.7%) with symp-
toms and substantial single point hyperglycaemia (fast-
ing plasma glucose 15.4–18.6 and HbA1c 101 to 110
mmol/mol).
All participants had the opportunity to attend all six
‘core’ education sessions allowing a minimum 12-month
follow-up, but the trial end date of 31.03.2018 precluded
all participants receiving all maintenance sessions (max-
imum 15) or receive all DPM calls (maximum 18). The
median number of the six ‘core’ education sessions
attended for both the INT and INT-DPM groups was 5
[interquartile range (IQR) = 2] (mean 4.7 (SD 1.5) INT,
and 4.2 (1.9) INT-DPM) for participants who did not
withdraw at any point during the programme. Interven-
tion groups combined reported an overall attendance
rate for core sessions of 78% (78.1% INT; 77.9% INT-
DPM), with 98% of participants attending at least one
core education session. Attendance rates and propor-
tions were calculated for participants who did not with-
draw during the programme (INT n = 89; INT-DPM n
= 85). Intervention groups combined reported a 43.1%
attendance at maintenance session (43.0% INT; 43.1%
INT-DPM). The total number of telephone calls made
to all participants in the INT-DPM arm in this trial was
1721. The mean percentage of connected calls based on
participants’ randomisation date to trial (maximum 18)
was 72.6% (SD 0.25), with a median connection rate of
80%.
Primary outcome
The primary outcome (mean HbA1c) in each group at
12 months was CON 48.5 (9.1) mmol/mol, INT 46.5
(8.1) mmol/mol, and INT-DPM 45.6 (6.0) mmol/mol.
The estimate of the difference in mean HbA1c by treat-
ment arms (Table 2) showed the combined intervention
arm had a significantly lower mean adjusted HbA1c than
CON, and this difference remained significant after im-
putation analysis (p = 0.007). The only significant ad-
justed difference between arms was in the INT-DPM vs
CON comparison (p = 0.007). At baseline, nearly all par-
ticipants in each arm were already achieving the QOF
[24] glycaemic targets of HbA1c < 58 or < 86mmol/mol
(Table 1). At 12 months, the equivalent data for the
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percentage of participants attaining HbA1c < 58 mmol/
mol were CON 89.9%, INT 92.1%, and INT-DPM 95.0%,
and for participants attaining HbA1c < 86mmol/mol,
the equivalent figures were 99%, 99%, and 100% respect-
ively. There were no important harms or serious adverse
events recorded.
Subgroup analyses
Pre-specified subgroup analyses showed no significant
interaction in the primary end point with sex,
deprivation score, or BMI (Table 3). There was, however,
a significant interaction between age in the INT-DPM vs
CON comparison, with greater effects among those aged




Age (years) 149 63.5 (10.0) 142 64.6 (10.1) 141 64.1 (9.9)
Sex (n; %)
Male 149 63 (42.3%) 142 61 (43.0 %) 141 57 (40.4%)
Female 86 (57.7%) 81 (57.0%) 84 (59.6%)
Family history type 2 diabetes (n; %) 149 73 (49.0 %) 142 58 (40.8%) 141 63 (44.7%)
Ethnicity
White 148 91.9 140 96.4 141 92.9
South Asian 1.4 1.4 3.5
Black 1.4 1.4 1.4
Others (%) 5.4 0.7 2.1
Family history cardiovascular disease (n; %) 13 (8.7) 22 (15.5) 25 (17.7)
Social deprivation scorea 149 16.8 (10.6) 142 17.2 (13.7) 141 16.3 (9.5)
Weight (kg) 149 93.3 (19.3) 142 93.0 (17.4) 141 93.7 (19.7)
Body mass index (kg/m2) 149 32.4 (6.4) 142 32.4 (5.4) 141 32.8 (6.4)
Waist circumference (cm) 149 108.6 (14.2) 142 108.5(12.5) 141 109.1 (14.2)
Body fat mass (kg)b 142 35.9 (9.6) 139 36.5 (9.1) 138 36.2 (8.7)
Visceral fat scoreb 142 15.2 (5.2) 139 15.4 (4.6) 138 16.0 (5.7)
HbA1c (mmol/mol) 149 52.5 (10.2) 142 52.7 (11.3) 141 51.1 (8.1)
HbA1c < 58 mmol/mol (n; %)c 149 129 (86.6%) 142 124 (87.3%) 141 129 (91.5%)
HbA1c < 86 mmol/mol (n; %)c 149 147 (98.7%) 142 136 (95.8%) 141 139 (98.6%)
Fasting plasma glucose (mmol/l) 149 7.2 (1.7) 142 7.3 (1.8) 141 7.1 (1.4)
Fasting HDL cholesterol (mmol/l) 140 1.26 (0.3) 136 1.22 (0.3) 139 1.23 (0.36)
Fasting LDL cholesterol (mmol/l) 136 3.2 (1.1) 135 3.1 (1.0) 136 3.1 (1.1)
Fasting plasma insulin (pmol/l) 142 106.3 (65.6) 133 137.1 (107) 138 124.3 (87.1)
HOMA insulin sensitivity (%)d 141 70.4 (54.3) 131 55.9 (38.8) 137 59.3 (39.5)
HOMA beta cell function (%)d 141 77.2 (36.8) 131 93.3 (57.6) 137 88.6 (48.3)
Physical activity: MET minutes per weeke 97 2523 (2590) 97 2786 (2861) 96 2786 (2912)
Physical activity: minutes sitting per weeke 107 445 (258) 106 527 (336) 99 473 (265)
Dietary fibre intake scalef 112 2.46 (0.37) 116 2.40 (0.38) 111 2.41 (0.38)
Dietary fat scalef 114 2.32 (0.32) 116 2.33 (0.31) 111 2.38 (0.28)
ADD QoLg 106 1.41 (0.94) 108 1.17 (1.1) 100 1.1 (1.01)
W-BQ12g 106 25.8 (5.7) 102 23.6 (7.5) 98 22.7 (7.7)
EQ-5Df 111 0.84 (0.18) 112 0.82 (0.23) 108 0.75 (0.27)
Data are shown as mean and standard deviation (SD) for continuous variables or as n (%) for categorical variables. n columns show the data available for each
variable for each group. aIMD Index of Multiple Deprivation mean score. bBody fat by Tanita body composition analyser. cQuality and Outcomes Framework (QOF)
glycaemic attainment. dHomeostasis model assessment (HOMA) of baseline insulin sensitivity (S) and beta cell function (B) expressed as percentage of standard
reference range. ePhysical activity scales derived from international physical activity questionnaire IPAQ. f Dietary fat and fibre scores based on self-reported Diet
Behaviour Questionnaire (DBQ)—higher scale score indicates lower fat intake. gWell-being score (WBQ-12) questionnaire, health-related quality of life score (EQ-
5D) questionnaire, and Audit of Diabetes-Dependent Quality of Life (ADDQoL)
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Fig. 1 CONSORT diagram: participant flow through trial arms
Table 2 Primary outcome: estimates of difference at 12 months between treatment arms in mean HbA1c (mmol/mol) shown as
effect size and 95% confidence interval
Analysis INT-DPM vs INT p INT vs CONTROL p INT- DPM vs CONTROL p Combined INT vs
CONTROL
p
Adjusted −0.55 (−2.46, 1.35) 0.57 −2.14 (−4.33, 0.05) 0.06 −2.57 (−4.52,−0.61) 0.01 −2.38 (−4.08, −0.68) 0.01
Imputed adjusted −0.83 (−2.82, −1.15) 0.41 −1.92 (−4.01, 0.18) 0.07 −2.62 (−4.50, −0.74) 0.007 −2.30 (−3.96, −0.64) 0.007
INT, standard intervention group; INT-DPM, intervention group with diabetes prevention mentors (DPM); combined intervention, both intervention groups
combined; CONTROL, control arm without trial intervention; Adjusted, analysis corrected for baseline HbA1c and imputed for missing data. The Combined INT vs
CONTROL comparison is a post hoc analysis
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< 65 years (difference in mean HbA1c −6.0 mmol/mol;
95% CI −9.56, −2.46) compared to those aged over 65
years (−0.22mmol/mol; 95% CI −2.70, 2.25; interaction
p = 0.007). There was a trend towards a greater inter-
vention effect size in those in the higher BMI quartiles
(Table 4). Post hoc trend analysis showed this trend was
significant for the combined group vs control arm com-
parison (p = 0.04), but not for the other comparisons be-
tween arms.
Self-reported oral hypoglycaemic (OHG) use at 12
months was CON 44/113 (38.9%), INT 37/93 (39.8%),
and INT-DPM 32/88 (36.4%), and 92.5% of OHG use
was metformin alone. The adjusted HbA1c effect in
intervention arms was statistically significant only in
those self-reporting OHG use at 12 months compared to
controls (Table 4). This effect was significant in the
combined intervention vs controls (Table 4), and only
significant in the INT-DPM arm vs controls. The partici-
pants who were recorded at 12 months as taking OHG,
when compared to those not taking OHG at 12 months,
did not differ in mean age at randomisation (65.2 [9.5]
years vs 62.6 [9.4] years), or mean BMI (31.8 [5.8] vs
33.1 [6.5] kg/m2), but had a higher mean HbA1c at
randomisation (58.1 [14.5] mmol/mol vs 50.0 [6.3]
mmol/mol; p = 0.0001)
Secondary outcomes
Descriptive data by arm and adjusted differences for sec-
ondary outcomes are shown in Tables 5 and 6 and in
Additional file 4. There were no significant adjusted dif-
ferences between groups at 12 and 24 months in biomet-
ric or body composition measures, or in health-related
quality of life. There was however a significant improve-
ment in fat intake score between INT-DPM and INT
group at 12 months (Table 5), and between INT-DPM
and CON at 24 months, and an increase in physical ac-
tivity (resistance activity days per week) at 12 months in
both intervention groups compared to controls. There
were no significant unadjusted differences between trial
arms in DTSQ or DMSES mean scores at 12 or 24
months (data not shown). Questionnaire data on dia-
betes treatment satisfaction and self-efficacy (DTSQ and
DMSES) were not collected at baseline as participants
were screen detected and newly diagnosed, and the use
of these psychometrically validated questionnaires would
be outside licence in newly diagnosed patients. Later
Table 3 Subgroup analysis: estimate of adjusted difference in mean HbA1c (mmol/mol) at 12 months between treatment arms by
age, sex, deprivation score, and body mass index subgroup
INT-DPM vs INT p INT vs CONTROL p INT- DPM vs CONTROL p Combined intervention
vs CONTROL
p
Male −0.13 (−2.38, 2.13) 0.42 −3.78 (−6.81, −0.74) 0.1 −3.90 (−6.91, −0.89) 0.29 −3.84 (−6.18, −1.49) 0.09
Female −1.78 (−5.28, 1.72) 0.19 (−3.43, 3.82) −1.58 (−4.59, 1.43) −0.70 (−3.56, 2.17)
Age < 65 years −2.55 (−5.55, 0.46) 0.15 −3.46 (−7.53, 0.62) 0.24 −6.01 (−9.56, −2.46) 0.007 −4.76 (−7.75, −1.78) 0.02
Age ≥ 65 years 0.46 (−2.25, 3.16) −0.68 (−3.31, 1.96) −0.22 (−2.70, 2.25) −0.46 (−2.67, 1.75)
Deprivation quartile 1 (low) −1.1 (−4.43, 2.24) 0.27 0.58 (−2.53, 3.68) 0.41 −0.52 (−3.96, 2.93) 0.48 0.07 (−2.78,2.92) 0.42
Deprivation quartile 2 2.2 (−0.82, 5.22) −4.9 (−9.49, −0.31) −2.7 (−7.4, 2.0) −3.8 (−7.33, −0.27)
Deprivation quartile 3 −1.59 (−5.19, 2) −1.94 (−5.96, 2.08) −3.53 (−7.44, 0.37) −2.72 (−5.84, 0.41)
Deprivation quartile 4 (high) −3.29 (−9.34, 2.77) −1.84 (−8.73, 5.06) −5.13 (−10.23, −0.02) −3.55 (−8.55, 1.45)
aBody mass index quartile
1 (low)
−0.21 (−3.06, 2.65) 0.34 −0.25 (−2.79, 2.28) 0.23 −0.46 (−3.1, 2.18) 0.35 −0.34 (−2.46, 1.78) 0.21
Body mass index quartile 2 −3.75 (−8.35, 0.85) 0.02 (−5.52, 5.55) −3.73 (−7.43, −0.03) −1.76 (−5.93, 2.41)
Body mass index quartile 3 1.01 (−3.69, 5.71) −3.27 (−8.6, 2.05) −2.26 (−6.68, 2.16) −2.64 (−6.5, 1.21)
Body mass index quartile
4 (high)
−0.34 (−4.11, 3.43) −5.52 (−11.15, 0.1) −5.86 (−12.0, 0.31) −5.68 (−10.11, −1.25)
Data are shown as effect size and 95% confidence interval, and the p value is for interaction within each subgroup (age, sex, deprivation score, and body mass
index). Adjusted for baseline data
Table 4 Post hoc subgroup analysis: analysis of adjusted differences in mean HbA1c at 12 months by self-reported oral
hypoglycaemic use shown as effect size and 95% confidence interval
Analysis INT-DPM vs INT p INT vs CONTROL p INT-DPM vs CONTROL p Combined INT vs
CONTROL
p
Oral hypoglycaemic use −2.8 (−7.2, 1.49) 0.19 −4.2 (−9.3, 0.77) 0.09 −7.0 (−11.5, −2.5) 0.003 −5.45 (−9.3, −1.6) 0.006
No oral hypoglycaemic use −0.79 (−1.12, 2.69) 0.41 −0.93 (−2.46, 0.59) 0.23 − 0.68 (2.27, 0.92) 0.40 − 0.7 (−2.92, 0.72) 0.33
Adjusted for baseline Hba1c data
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DTSQ and DMSES data could not therefore be adjusted
for baseline differences. Further descriptive data at 12
and 24 months are shown in Additional file 4: Tables A
and B.
Dose of intervention attained and outcomes
For the INT arm (n = 142), 50 (35.2%), 32 (22.5%), and
60 (42.3%) were defined as attaining a low, moderate, or
high dose of the intervention, respectively. For the INT-
DPM arm (n = 141), the equivalent data were 57
(40.4%), 32 (22.7%), and 52 (36.9%). The ‘dose’ effect by
intervention arm at 12 and 24 months is shown (Table 7)
compared to the low-dose attainment group. There was
no significant dose-response’ effect in HbA1c or weight
in the INT-DPM group (Table 7). However, the INT
group maintained significantly more weight loss to 24
months in those attaining a high dose compared to those
attaining a low dose (−5.19 kg; −9.65, −0.74; p = 0.02).
Health economic analysis
There was an unexplained baseline imbalance in EQ5D
scores (Table 1) and return rates for these question-
naires were low at 24 months in each arm: CON (n = 64;
43%), INT (n = 41; 29%), and INT-DPM (n = 31; 22%).
The estimates of QALY and incremental cost-
effectiveness ratio (ICER) per QALY were therefore not
robust and have not been presented.
Additional non-pre-specified post hoc analyses
We defined diabetes ‘remission’ in a post hoc non-pre-
specified analysis at 12 months as HbA1c < 48 mmol/
mol combined with a fasting plasma glucose < 7.0 mmol/
l. Using these criteria, at 12 months, remission rates were
CON 61/119 (51.2%), INT 62/100 (62%), and INT-DPM
56/97 (57.7%).
Discussion
In this trial, people with newly diagnosed, screen-
detected type 2 diabetes received a group-delivered diet
and lifestyle intervention, known to be effective in redu-
cing the incidence of type 2 diabetes in high-risk groups
[21]. Here, we found the same NDPS lifestyle interven-
tion led to a modest but significant improvement in gly-
caemic control, particularly for participants receiving
additional lifestyle support from trained peer volunteers
with type 2 diabetes (DPM). Improvement in mean
HbA1c was better in younger participants, and in those
self-reporting oral hypoglycaemic use at 12 months.
These effects were also most significant in the group re-
ceiving additional support from trained volunteers with
type 2 diabetes. The glycaemic benefit was less, and not
statistically significant, at 24 months.
The value of structured education and lifestyle self-
management programmes for people with type 2
diabetes is well established [7–11, 51, 52]. Analysis of
clearly defined structured education interventions show
a significant reduction in HbA1c, greater efficacy in in-
terventions of more than 12 h in total, and that group
support is at least as effective as an individual interven-
tion [51, 52]. In the UK, national recommendations are
that diabetes self-management and education should be
delivered by trained educators from a range of back-
grounds, using an evidence-based curriculum that is
quality assured, and initiated at diagnosis [7]. The NDPS
lifestyle intervention meets these criteria, has a strong
theoretical base in behaviour change and learning theor-
ies [21, 22, 24], and can now be added to the small list
of lifestyle programmes with trial evidence for efficacy
[7], or where a lifestyle prevention intervention has
shown glycaemic benefit in type 2 diabetes [53].
The improvement in HbA1c in this trial was most
consistent in the intervention arm supported by diabetes
prevention mentors (INT-DPM). The statistically signifi-
cant subgroup effects in the younger age group (< 65
years old), and in those self-reporting OHG use at 12
months, were also confined to the INT-DPM group.
There were significant changes in reported lifestyle be-
haviours in intervention participants. At 12 months, diet-
ary fat scores in the INT-DPM group were significantly
different compared to INT arm alone, suggesting INT-
DPM participants changed behaviour related to dietary
fat reduction compared to the standard intervention arm
(INT). The EPIC-Norfolk cohort study, in a population
similar to ours, reported a significant direct association
between dietary fat intake and HbA1c in type 2 diabetes
[54], and this may be a mechanism in the current study.
Both intervention groups also showed significant im-
provement in physical activity (resistance exercise days
per week) compared to controls at 12 and 24months.
The possible longer term clinical benefit of the small
intervention effect size we observed in mean HbA1c (be-
tween −2 and −3 mmol/mol at 12 months compared to
controls, and not sustained to 24 months) is unclear and
may not translate to better clinical outcomes. This could
only be answered by a long-term follow-up. The HbA1c
effect size in this trial is certainly less than the HbA1c
effect size seen in meta-analysis of the type 2 diabetes
intensive treatment trials that have shown outcome
benefit for microvascular end points [55]. Prospective
follow-up of people with newly diagnosed type 2 dia-
betes in a broadly similar population [56], however, has
shown that higher HbA1c at 12 months does have pre-
dictive value for later complications. Even small early
differences in HbA1c are associated with later outcomes,
with a 1.1 mmol/mol increase in HbA1c associated with
a significant increased later microvascular risk (OR 1.14;
1.05,1.24) [56]. In the trial reported here, the HbA1c re-
duction effect was greater (−6 to −7 mmol/mol) in
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younger participants, in those receiving oral hypoglycae-
mics, and in more obese subgroups, and longer term
benefit would be more likely at this level of effect and in
these groups [55, 56]. It should also be emphasised that
while there are epidemiological direct associations be-
tween HbA1c and adverse macrovascular and micro-
vascular complications in type 2 diabetes, therapy-driven
HbA1c reductions may have differential effects on
macrovascular and microvascular outcomes [55, 57, 58].
There was a substantial loss to follow-up in trial after
12 months (Fig. 1), and the main reason for withdrawal
was that participants were unwilling to continue. It
should be emphasised that the participants in this trial
had been invited to screening primarily for a diabetes
prevention research programme, as they were at in-
creased risk of type 2 diabetes, and that the 9% of the
eligible population we screened were therefore a self-
selecting population interested in their diabetes risk—
25% of those with screen-detected type 2 diabetes de-
clined randomisation after diagnosis (Fig. 1). It is pos-
sible also that participants in this trial with screen-
detected type 2 diabetes were less willing to continue
after diagnosis with a lifestyle intervention developed
and presented primarily as diabetes prevention lifestyle
intervention. These factors should be taken into account
in terms of translation to other type 2 diabetes
populations, and the generalisability of our findings to
non-research clinical settings.
The use of trained lay volunteers (with or without dia-
betes) to support the clinical management of people with
type 2 diabetes is an attractive model in terms of work-
force planning and limiting cost [12–18, 59–67]. The level
of input from trained lay volunteers can range from par-
ticipating in simple support groups to acting as a leading
provider of care and can be delivered in many clinical set-
tings alongside health care professionals (HCP) [59–67].
In type 2 diabetes, studies describing this model have
commonly been in high-income countries in minority
populations in low-income settings. These lay volunteer
workers have provided education, delivered a standard
curriculum, or provided informational and emotional sup-
port in addition to the support from HCP [12–18, 59–67].
The use of volunteer peer supporters with type 2 diabetes
themselves in delivering a lifestyle intervention with a
health care professional (HCP) to people with type 2 dia-
betes is a less common model that has shown inconsistent
outcomes [17, 59–67]. This study is the first to test the
added effect of volunteer peer intervention alongside
HCP, compared to HCP alone or a control group in newly
diagnosed type 2 diabetes.
Efficacy in participants receiving peer support may be
more apparent when the peers themselves have high
Table 5 Adjusted differences between groups at 12 months





Fasting plasma glucose (mmol/l) −0.17 (−0.54, 0.19) 0.35 −0.03 (−0.41, 0.35) 0.87 −0.21 (−0.52, 0.1) 0.19 −0.12 (−0.42, 0.18) 0.44
Weight (kg) −0.29 (−1.63, 1.05) 0.67 0.03 (−1.46, 1.53) 0.96 −0.34 (−1.82, 1.15) 0.66 −0.16 (−1.37, 1.05) 0.79
Body mass index (kg/m2) −0.13 (−0.6, 0.35) 0.60 0.06 (−0.46, 0.58) 0.82 −0.09 (−0.6, 0.43) 0.74 −0.02 (−0.44, 0.41) 0.94
Body fat (%)a −0.4 (−1.4, 0.6) 0.43 0.93 (1.9, 2.01) 0.09 0.54 (−0.45, 1.54) 0.28 0.74 (−0.12, 1.59) 0.09
Body fat mass (kg)a −0.57 (−1.82, 0.69) 0.38 0.7 (−0.7, 2.1) 0.32 0.12 (−1.15, 1.38) 0.86 0.41 (−0.69, 1.51) 0.46
Visceral fat scorea 0.29 (−0.17, 0.76) 0.21 −0.12 (−0.6, 0.37) 0.63 −0.38(− 0.9, 0.15) 0.16 −0.08 (−0.3, 0.49) 0.70
Waist (cm) 0.17 (−1.4,1.74) 0.83 0.33 (−1.29, 1.95) 0.69 0.44 (−1.24, 2.13) 0.61 0.37 (−0.99, 1.73) 0.59
Physical activity: MET min/weekb −958 (−2192, 276) 0.13 671 (−478, 1820) 0.25 −234 (−1478, 1011) 0.71 298 (−680, 1277) 0.55
Physical activity: resistance
days/wkb
0.71 (0.29, 1.70) 0.44 4.22 (1.71, 10.44) 0.01 3.32 (1.25,8.80) 0.02 3.81 (1.69, 8.61) 0.01
Physical activity: min sitting/wkb 71.8 (−33, 176) 0.18 −33 (−121, 54) 0.45 38.1 (−56, 133) 0.43 −0.03 (−78, 77) 1.0
Fat scale scorec 0.17 (0.05, 0.29) 0.01 −0.26 (−0.07, 0.58) 0.28 0.11 (0, 0.23) 0.06 0.02 (−0.08, 0.11) 0.74
Fibre scale scorec −0.01 (−0.15, 0.13) 0.92 −0.05 (−0.15, 0.05) 0.57 0.01 (−0.12, 0.14) 0.84 0.02 (−0.08, 0.12) 0.71
General well-being score
WBQ-12d
−0.54 (−2.35, 1.27) 0.55 −0.12 (−1.21, 1.44) 0.86 −0.61 (−2.16, 0.94) 0.44 −0.27 (−1.52, 0.99) 0.68
EQ-5Dd 0.06 (0, 0.12) 0.07 −0.03 (−0.09, 0.02) 0.25 0.03 (−0.03, 0.09) 0.36 0 (−0.05, 0.04) 0.86
ADDqold −0.17 (−0.49, 0.16) 0.31 0.1 (−0.18, 0.37) 0.48 −0.06 (−0.34, 0.21) 0.65 0.03 (−0.2, 0.27) 0.79
HOMA–B (%)e −5.6 (−13.89, 2.68) 0.18 3.38 (−4.8, 11.5) 0.42 −0.43 (−7.53, 6.67) 0.91 1.37 (−5.24, 7.97) 0.68
HOMA–S (%)e 5.28 (−5.87, 16.44) 0.35 −3.6 (−15.3, 8.1) 0.55 −1.01 (−14.65, 12.63) 0.88 −1.32 (−11.71, 9.07) 0.80
Data adjusted for baseline value for each variable and shown as change in mean and 95% CI. aFat mass (kg and %) by Tanita body composition analyser.
bPhysical activity scales derived from international physical activity questionnaire IPAQ. cDietary fat and fibre scores based on self-reported Diet Behaviour
Questionnaire (DBQ)—higher fat scale scores indicate lower fat intake. dWell-being score (WBQ-12) questionnaire, health-related quality of life score (EQ-5D)
questionnaire, and ADDQoL. eHomeostasis model assessment (HOMA) of baseline insulin sensitivity (S) and beta cell function (B)
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levels of self-efficacy [68, 69]. In this study, DPM
diabetes-specific self-efficacy levels were high, and as a
group, they were similar in age, medication use,
diabetes-specific self-efficacy scores, and well-being
(WBQ12) scores as the INT-DPM participants. By defin-
ition, the DPM had experienced a longer duration of
diabetes than the trial participants had, and 65% of the
DPM had had type 2 diabetes for > 4 years [22]. Non-
adherence to oral hypoglycaemic use, particularly met-
formin, in people with type 2 diabetes is often high, with
high discontinuation rates [70, 71]. Improved adherence
to metformin or other OHG use is associated with better
glycaemic control [72] and community health worker or
peer support in people with type 2 diabetes may improve
medication adherence [65, 73, 74]. However, we did not
undertake formal objective assessment of medication ad-
herence other than self-reported measures. DPM train-
ing did not allow them to discuss changes in medication
directly with participants, and further work should see if
active DPM support for medication adherence further
improves outcomes in the NDPS intervention. The effect
size in mean HbA1c in this trial was significantly greater
in those < 65 years old compared to those > 65 years old,
and a similar age effect is apparent in meta-analysis of
lifestyle and behavioural programmes in type 2 diabetes
[52]. A greater glycaemic benefit for peer intervention in
type 2 diabetes has been described when the peers are
older than the participants and in younger participants
[75–77].
The participants randomised in this trial were diag-
nosed as having type 2 diabetes with the current diag-
nostic criteria being used between 2011 and 2017 and
would be regarded as having reasonable glycaemic con-
trol with nearly 90% having a baseline HbA1c < 58
mmol/mol. It is important to make a distinction between
people with screen-detected diabetes (as in NDPS) and
newly diagnosed type 2 diabetes, as the former have a
better prognosis [78], and the potential for reducing
HbA1c in newly diagnosed populations is more limited
than in populations with higher baseline HbA1c [79].
Lifestyle intervention programmes in type 2 diabetes
have usually studied populations with established or
newly diagnosed type 2 diabetes and as far as we are
aware have not been used in screen-detected type 2 dia-
betes. The DESMOND type 2 diabetes education
programme for patients with established or newly diag-
nosed T2DM had an estimated cost-effectiveness ICER
of £5,387 per QALY, but has not been applied to screen-
Table 6 Adjusted differences between groups at 24 months





HbA1c (mmol/mol) 0.11 (−2.46, 2.67) 0.93 −1.29 (−3.77, 1.19) 0.31 −1.18 (−3.8, 1.5) 0.38 −1.24 (−3.35, 0.87) 0.25
Fasting plasma glucose
(mmol/l)
−0.09 (−0.5, 0.32) 0.66 0.01 (−0.38, 0.41) 0.95 −0.06 (−0.5, 0.4) 0.78 −0.03 (−0.36, 0.31) 0.87
Weight (kg) −0.46 (−2.43, 1.51) 0.39 −1.51 (−4.97, 1.94) 0.39 −1.93 (−5.6, 1.7) 0.30 −1.7 (−4.34, 0.94) 0.2
Body mass index (kg/m2) −0.17 (−0.87, 0.54) 0.46 −0.47 (−1.72, 0.79) 0.46 −0.63 (−1.96, 0.7) 0.35 −0.54 (−1.5, 0.41) 0.26
Body fat (%)a −0.29 (−1.65, 1.07) 0.67 1.46 (−0.02, 2.94) 0.05 1.14 (−0.32, 2.59) 0.13 1.3 (0.1, 2.49) 0.03
Body fat mass (kg)a −0.62 (−2.36, 1.12) 0.48 0.98 (−0.95, 2.92) 0.32 0.37 (−1.58, 2.33) 0.71 0.69 (−0.87, 2.26) 0.38
Visceral fat scorea 0.16 (−0.5, 0.82) 0.63 −0.27 (−0.99, 0.45) 0.45 −0.36 (−1.15, 0.43) 0.37 −0.06 (−0.66, 054) 0.84
Waist (cm) 0.41 (−2.76, 1.93) 0.73 −0.05 (−1.91, 1.81) 0.87 −0.28 (−2.6, 2.1) 0.81 −0.05 (−1.91, 1.81) 0.96
Physical activity: MET min/weekb −698 (−2079, 683) 0.32 482 (−718, 1681) 0.43 −223 (−1433, 987) 0.71 198 (−823, 1220) 0.70
Physical activity: resistance
days/wkb
1.03 (0.32, 3.31) 0.96 2.06 (0.71, 5.99) 0.18 1.71 (0.59, 4.94) 0.32 1.90 (0.79, 4.59) 0.15
Physical activity: min sitting/wkb −115 (−220, −11) 0.03 18.5 (−91.9, 129) 0.74 −94.6 (−200, 11) 0.08 −27.7 (−115, 60) 0.53
Fat scale scorec 0.04 (−0.11, 0.18) 0.6 0.11 (−0.02, 0.23) 0.09 0.15 (0.02, 0.27) 0.02 0.12 (0.02, 0.23) 0.02
Fibre scale scorec 0.02 (−0.1, 0.15) 0.7 0.07 (−0.08, 0.21) 0.36 0.09 (−0.07, 0.25) 0.26 0.08 (−0.04, 0.19) 0.19
General well-being score
WBQ-12d
−0.91 (−2.91, 1.09) 0.37 1.09 (−0.69, 2.88) 0.23 0.48 (−1.41, 2.37) 0.62 0.76 (−0.76, 2.27) 0.33
EQ-5Dd −0.08 (−0.5, 0.33) 0.69 −0.07 (−0.43, 0.29) 0.7 −0.14 (−0.5, 0.22) 0.44 −0.1 (−0.4, 0.19) 0.5
ADDqold 0 (−0.07, 0.08) 0.97 −0.01 (−0.07, 0.05) 0.72 0 (−0.07, 0.07) 0.99 0 (−0.06, 0.05) 0.89
HOMA–B (%)e −3.05 (−14.5, 8.5) 0.6 2.8 (−7.04, 12.6) 0.57 1.41 (−7.47, 10.29) 0.75 2.32 (−6.02, 10.66) 0.58
HOMA–S (%)e −5.3 (−19.6, 8.9) 0.46 0.95 (−15.6, 13.7) 0.90 −5.88 (−20.9, 9.2) 0.44 −3.12 (−15.3, 9.05) 0.61
Data adjusted for baseline value for each variable and shown as change in mean and 95% CI. aFat mass (kg and %) by Tanita body composition analyser.
bPhysical activity scales derived from international physical activity questionnaire IPAQ. cDietary fat and fibre scores based on self-reported Diet Behaviour
Questionnaire (DBQ)—higher fat scale scores indicate lower fat intake. d Well-being score (WBQ-12) questionnaire, health-related quality of life score (EQ-5D)
questionnaire, and ADDQoL. eHomeostasis model assessment (HOMA) of baseline insulin sensitivity (S) and beta cell function (B)
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detected type 2 diabetes [79]. However, we would stress
that baseline imbalances in EQ-5D data between arms
and low questionnaire return rates at 12 and 24months
precluded a robust estimate of cost-effectiveness in this
current study.
The interest in type 2 diabetes ‘remission’ with lifestyle
change or treatment has grown in the last few years [80,
81], but was not part of the pre-specified analysis, or an
aim of this study. It is also difficult to define remission
with different glycaemic diagnostic categories. However,
at 12 months, more than half of all participants in each
arm recorded a biochemical remission with both an
HbA1c < 48 mmol/mol and a fasting plasma glucose <
7.0 mmol/l.
Limitations
The study population, and the DPM, were largely white
and it is unclear if these findings are generalisable to
other populations with Type 2 diabetes. The mechanism
of the effect of improved glycaemic control also needs
further exploration and would require a more detailed
collection of medication adherence data and the use of
objective dietary and physical activity measures. This is
important as the glycaemic effect of the intervention was
Table 7 Adjusted changes in weight, fasting plasma glucose, and HbA1c at 12 and 24months by participants achieving higher
‘dose’ of intervention (moderate, or high) compared to lowest dose participants in each intervention group
Intervention group Intervention group-DPM




1.69 (−3.4, 6.7) 0.50 −3.45 (−7.69, 0.78) 0.11 −3.00 (−6.88, 0.89) 0.13 −3.17 (−6.72, 0.38) 0.08
HbA1c (mmol/mol)
Unadjusted
−1.43 (−8.8, 6.0) 0.70 −8.96 (−15.6, −2.3) 0.01 0.9 (−3.81, 5.62) 0.70 1.56 (−2.7, 5.8) 0.47
Weight (kg)
Adjusted
1.36 (−2.5, 5.3) 0.48 −3.6 (−6.9, −0.2) 0.04 −0.73 (−4.67, 3.22) 0.71 −1.03 (−4.55, 2.49) 0.56
Weight (kg)
Unadjusted












−0.05 (−5.09, 5.00) 0.99 −3.77 (−8.31, 0.78) 0.10 4.71 (−1.62, 11.04) 0.14 2.29 (−3.44, 8.03) 0.42
HbA1c (mmol/mol)
Unadjusted
−0.21 (−6.9, 6.4) 0.95 −2.74 (−8.9, 3.5) 0.38 3.51 (−2.9, 9.9) 0.277 1.77 (−4.13, 7.67) 0.55
Weight (kg)
Adjusted
−2.18 (−7.41, 3.06) 0.40 −5.19 (−9.65, −0.74) 0.02 −1.45 (−6.07, 3.16) 0.52 −1.15 (−5.13, 2.83) 0.55
Weight (kg)
Unadjusted








0.02 (−1.34, 1.37) 0.98 − 0.17 (−1.43, 1.09) 0.79 0.16 (−0.76, 1.07) 0.73 0.44 (−0.45, 1.33) 0.32
Baseline factors adjusted for in dose-response modelling (considered to be potential confounders; Additional File 5; Figure 2) were based on a backward
elimination algorithm starting with all baseline measures, retaining those that were significant at the 5% level. Baseline factors adjusted for in dose-response
modelling were (a) 12 months INT HbA1c (HbA1c, fat scale score), 12 months INT weight (physical activity, gender, body fat mass, HbA1c, total met minutes per
week), and 12 months INT fasting plasma glucose (waist circumference , fasting plasma glucose, body fat mass, fat scale score, and HbA1c); (b) 12 months INT-
DPM HbA1c (HbA1c), 12 months INT-DPM weight (baseline BMI), and 12 months INT-DPM fasting plasma glucose (fasting glucose); (c) 24 months INT HbA1c
(HbA1c, visceral fat mass, deprivation index, fasting plasma glucose), 24 months INT weight (minutes sitting, weight, family history diabetes), and 24 months INT
fasting plasma glucose (age, visceral fat mass, fibre scale score, total MET minutes per week, deprivation index, body fat mass, fasting plasma glucose); and (d) 24
months INT-DPM HbA1c ( total MET minutes per week, HbA1c, EQ5D, deprivation index), 24 months INT-DPM weight (visceral fat mass, ADD QoL, weight, EQ5D,
deprivation index, HbA1c, fasting plasma glucose, total MET minutes per week), and 24 months INT-DPM fasting plasma glucose (fasting plasma glucose, body fat
mass, physical activity category, BMI, deprivation index). Data is also shown unadjusted for baseline variables
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associated with limited evidence for significant lifestyle
changes. This may reflect the complexity of the interven-
tion which had multiple behavioural targets and allowed
for considerable individual tailoring of lifestyle changes,
and some participants may have achieved better gly-
caemic control through weight loss and others through
engaging in either aerobic or resistance/muscle-strength-
ening exercise. The heterogeneity of pathways to benefit
is well recognised in complex behavioural interventions
[82]. The ‘dose response’ data presented in this manu-
script should also be interpreted cautiously, as this ana-
lysis was not based on participant randomisation or
power calculations, and a more detailed process analysis
will be undertaken to examine the complex causal path-
ways to any outcome benefit.
The role of the DPM in changes in dietary behaviour
and medication adherence and the mechanisms under-
lying the age effect are unclear. The improvement in gly-
caemic control is modest and lasted for 12 months, but
it is unknown if this would translate into longer term
benefit. The NDPS intervention was also not tested in
longer established type 2 diabetes populations and these
current data only apply to screen-detected populations,
and our health economic data for cost-effectiveness are
not robust enough to draw conclusions from. It is also
important to take into account the multiplicity of com-
parisons. For the primary analysis of the primary out-
come, for which there were 3 comparisons: (INT vs
CON, INT-DPM vs CON, and INT vs INT-SPM), a
Bonferroni correction would use a significance level of
1.7%. The main INT-DPM vs CON comparison (p =
0.007) is still highly significant at this level. There should
also be caution in attaching weight to relatively small
isolated significant effects in multiple secondary ana-
lyses. One limitation of our pre-specified SAP dose-
response modelling that should also be acknowledged is
that the decision of what factors to adjust the relation-
ship for was based on a backward elimination approach
which is based purely on statistical significance. An al-
ternative approach would have been the manual selec-
tion of covariates based on both clinical and statistical
significance.
Conclusions
This trial shows that a diet and lifestyle intervention
known to reduce the risk of type 2 diabetes [21] in high-
est risk glycaemic categories also has glycaemic benefit
in people with screen-detected type 2 diabetes when
delivered with peer volunteer support, with the most sig-
nificant effects seen at 12 months in younger participants
and in those taking oral hypoglycaemics. These effect
sizes were modest, however, and not sustained at 24
months. Our findings suggest that primary care
provision of lifestyle interventions to improve diabetes
outcomes could be enhanced with the additional support
of trained peer volunteers with type 2 diabetes. These
findings are relevant to the recent emphasis on
community-level interventions and social prescribing
through integrated care services or the voluntary sectors
[83]. This trial shows that the NDPS intervention has
value to clinicians and policy makers, as it is a lifestyle
intervention with trial evidence of benefit in both
screen-detected type 2 diabetes and in diabetes preven-
tion [21], and can be added to the small list of lifestyle
programmes with trial evidence for efficacy in type 2
diabetes [7].
Abbreviations
DPF: Diabetes prevention facilitator; DPM: Diabetes prevention mentors:
trained volunteers with type 2 diabetes; HCP: Health care professional;
ICER: Incremental cost-effectiveness ratio; IFG: Impaired fasting glucose;
NDH: Non-diabetic hyperglycaemia; NDPS: Norfolk Diabetes Prevention
Study; OHG: Oral hypoglycaemics; QALY: Quality-adjusted life year;
SAP: Statistical analysis plan
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12916-021-02053-x.
Additional file 1. NDPS protocol.
Additional file 2. Final statistical analysis plan.
Additional file 3. CONSORT checklist.
Additional file 4. Additional data Tables A and B.
Additional file 5: Figure 2: Directed acyclic graph (DAG).
Acknowledgements
We are grateful to Martin Pond and Tony Dyer (Norwich CTU).
Full NDPS group Sara Auckland, Max Bachmann, Garry Barton, Allan Clark,
Ketan Dhatariya, Clare Ferns, Nikki Garner, Colin Greaves, Andy Goldson,
Martin Hadley - Brown, Amanda Howe, Lisa Irvine, Garry John, Melanie
Pascale, David Rea, Jane Smith, Jeremy Turner, Rebecca Usher, Tara Wallace.
Authors’ contributions
MJS (CI) led on the study design, data interpretation, and writing. AC was
the co-investigator and trial statistician, led on the statistical analysis, and
contributed to the trial design, data interpretation, and writing. MB was the
co-investigator and contributed to the trial design, data interpretation, and
writing. NG contributed to the trial design, data interpretation, data analysis,
and writing and led on the DPM. LI led on health economic analysis and on
data interpretation and writing AH was a co-investigator and contributed to
the trial design, data interpretation, and writing.CG was a collaborator and
led on the intervention design and delivery, data interpretation, and writing. SA
contributed to the intervention design, data interpretation, and writing. JS was
a a co-investigator and contributed to the trial design, data interpretation, and
writing. JT was a co-investigator and contributed to the trial design, data
interpretation, and writing. DR was a co-investigator and contributed to the trial
design, participant engagement, and writing. GR was a collaborator and
contributed to the data collection and writing. KD was a co-investigator and
contributed to the trial design, data interpretation, and writing. GJ was a co-
investigator and contributed to the trial design, data interpretation, and writing.
GB was a co-investigator and contributed to the trial design, health economic
analysis, data interpretation, and writing. RU contributed to the data collection,
intervention design, and writing. CF contributed to the data collection, analysis,
and writing. MP contributed to the data analysis, data interpretation,
programme management, and writing. The authors read and approved the final
manuscript.
Sampson et al. BMC Medicine          (2021) 19:183 Page 14 of 17
Funding
The funder of the study had no role in the study design, data collection,
data analysis, data interpretation, or writing of the report. The corresponding
author had full access to all the data in the study and had final responsibility
for the decision to submit. This work was funded by the National Institute of
Health Research (NIHR) Programme Grant NIHR RP - PG – 0109 – 10013. This
article presents independent research funded by the National Institute for
Health Research (NIHR) under the Programme Grants for Applied Research
programme. The views expressed in this publication are those of the authors
and not necessarily those of the NIHR or the Department of Health and
Social Care.
Availability of data and materials
The dataset used in this publication is available from the corresponding
author on reasonable request.
Declarations
Ethics approval and consent to participate
Ethical issues: Ethical approval was obtained from the National Research
Ethics Service (NRES), Essex 1 Research Ethics Committee (10/H0301/55;
January 13, 2011), and all participants gave written informed consent. NDPS




The authors declare that they have no competing interests.
Author details
1Elsie Bertram Diabetes Centre, Department of Diabetes and Endocrinology,
Norfolk and Norwich University Hospital NHS Trust, Colney Lane, Norwich
NR4 7UY, UK. 2Norwich Medical School, University of East Anglia, Norwich,
UK. 3School of Sport, Exercise & Rehabilitation Sciences, University of
Birmingham, Birmingham, UK. 4University of Exeter Medical School, College
of Medicine & Health, University of Exeter, Exeter, UK. 5Department of
Diabetes and Endocrinology, Ipswich General Hospital NHS Trust, Ipswich,
UK. 6Department Clinical Biochemistry, Norfolk and Norwich University
Hospital NHS Trust, Norwich, UK.
Received: 9 March 2021 Accepted: 6 July 2021
References
1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al.
Global and regional diabetes prevalence estimates for 2019 and projections
for 2030 and 2045: results from the International Diabetes Federation
Diabetes Atlas, 9th edition. Diab Res Clin Pract. 2019;157:107843.
2. Comment. Reducing global diabetes burden by implementing solutions
and identifying gaps: a Lancet Commission. Lancet. 2016;387:1494–5.
3. Whicher CA, O’Neill S, Holt RIG. Diabetes in the UK: 2019. Diabet Med. 2020;
37:242–7.
4. National Institute for Health and Clinical Excellence. Public health draft
guidance. Preventing type 2 diabetes: risk identification and interventions
for individuals at high risk. National Institute for Health and Clinical
Excellence, London; Available from https://www.nice.org.uk/guidance/ph38.
2012. Last accessed 12.2.21
5. Hemmingsen B, Gimenez-Perez G, Mauricio D, Roqué I Figuls M, Metzendorf
MI, Richter B. Diet, physical activity, or both for prevention of delay of type
2 diabetes and its associate complications in people at increased risk of
developing type 2 diabetes mellitus. Cochrane Database of Systematic
Reviews. 2017; Issue 12 Art No. CD003054 www.cochranelibrary.com (last
accessed 4.8.20)
6. Galavitz KI, Weber MB, Straus A, Haw JS, Narayan KM, Ali MK. Global
Diabetes Prevention Interventions: a systematic review and network meta-
analysis of the real world impact on incidence, weight, and glucose.
Diabetes Care. 2018;41:1526–34.
7. National Institute for Health and Social Care Excellence (NICE). Quality
standard 6; Quality statement 2: structured education programmes for
adults with type 2 diabetes. August 2016; www.nice.org.uk (last accessed 12.
1.20)
8. Franz MJ, Boucher JL, Rutten-Ramos S, Van Wormer JJ. Lifestyle weight loss
intervention outcomes in overweight and obese adults with type 2
diabetes: a systematic review and meta-analysis of randomised clinical trials.
J Acad Nutr Diet. 2015;115:1447–63.
9. Terranova CO, Brakenridge CL, Lawler SP, Eakin EG, Reeves MM.
Effectiveness of lifestyle-based weight loss interventions for adults with type
2 diabetes: a systematic review and meta-analysis. Diab Obes Metab. 2015;
17:371–8.
10. Sherifali D, Bai JW, Kenny M, Warren R, Ali MU. Diabetes self-management
programmes in older adults: a systematic review and meta-analysis. Diab
Med. 2015;32:1404–14.
11. Doshmangir P, Jahangiry L, Farhangi MA, Doshmangir L, Faraji L. The
effectiveness of theory- and model-based lifestyle interventions on HbA1c
among patients with type 2 diabetes: a systematic review and meta-
analysis. Public Health. 2018;155:133–41.
12. Zhang X, Yang S, Sun K, Fisher EB, Sun X. How to achieve better effect of
peer support among adults with type 2 diabetes: a meta-analysis of
randomised controlled trials. Patient Educ Couns. 2016;99:186–97.
13. Dale J, Williams S, Bowyer V. What is the effect of peer support on diabetes
outcomes in adults? A systematic review. Diab Med. 2012;29:1361–77.
14. Fisher EB, Boothroyd RI, Elstad EA, Hays L, Henes A, Maslow GR, et al. Peer
support of complex health behaviors in prevention and disease
management with special reference to diabetes: systematic reviews. Clin
Diab Endocrinol. 2017;3:4. https://doi.org/10.1186/s40842-017-0042-3.
15. Perry HB, Zulliger R, Rogers MM. Community health workers in low, middle,
and high income countries: an overview of their history, recent evolution,
and current effectiveness. Annu Rev Public Health. 2014;35:399–421.
16. Egbujie BA, Delobelle PA, Levitt N, Puoane T, Sanders D, van Wyk B. Role of
community health workers in type 2 diabetes mellitus self-management: a
scoping review. Plos One. 2018;13:e0198424.
17. Gatlin TK, Serafica R, Johnson M. Systematic review of peer education
intervention programmes among individuals with type 2 diabetes. J Clin
Nurs. 2017;26:4212–22.
18. Spencer MS, Kieffer EC, Sinco B, Piatt G, Palmisano G, Hawkins J, et al.
Outcomes at 18 months from a community health worker and peer leader
diabetes self-management program for Latino adults. Diab Care. 2018;41:
1414–22.
19. Fisher EB, Boothroyd RI, Coufal MM, Baumann LC, Mbanya JC, Rotheram-
Borus MJ, et al. Peer support for self-management of diabetes improved
outcomes in international settings. Health Aff. 2012;31:130–9.
20. Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W,
et al. The behavior change technique taxonomy (v1) of 93 hierarchically
clustered techniques: building an international consensus for the reporting
of behavior change interventions. Ann Behav Med. 2013;46:81–95.
21. Sampson M, Clark A, Bachmann M, Garner N, Irvine L, Howe A, et al.
Lifestyle intervention with or without lay volunteers to prevent type 2
diabetes in people with impaired fasting glucose and/or nondiabetic
hyperglycemia: a randomized clinical trial. JAMA Intern Med. 2021;181:168–
78.
22. Garner NJ, Pascale M, France K, Ferns C, Clark A, Auckland S, et al.
Recruitment, retention, and training of people with type 2 diabetes as
diabetes prevention mentors (DPM) to support a health care professional
delivered diabetes prevention program: the Norfolk Diabetes Prevention
Study (NDPS). BMJ Open Diab Res Care. 2019;7:e000619. https://doi.org/1
0.1136/bmjdrc-2018-000619.
23. Sampson M, Elwell-Sutton T, Bachmann MO, Clark A, Dhatariya KK, Ferns C,
et al. Discordance in glycaemic categories and regression to normality at
baseline in 10,000 people in a type 2 diabetes prevention trial. Sci Rep.
2018;19:6240.
24. Pascale M, Murray N, Bachmann M, Barton G, Clark A, Howe A, et al. The
Norfolk Diabetes Prevention Study [NDPS]: a 46 month multi-centre,
randomised, controlled parallel group trial of a lifestyle intervention [with or
without additional support from lay lifestyle mentors with type 2 diabetes]
to prevent transition to type 2 diabetes in high risk groups with non-
diabetic hyperglycemia, or impaired fasting glucose. BMC Public Health.
2017;17:31.
25. International Expert Committee (IEC) International expert committee report
on the role of the HbA1c assay in the diagnosis of diabetes. Diab Care
2009; 32: 1327 – 1334.
Sampson et al. BMC Medicine          (2021) 19:183 Page 15 of 17
26. WHO. Definition and diagnosis of diabetes mellitus and intermediate
hyperglycemia: report of a WHO/IDF consultation. Report of a WHO
consultation. 1999 http://whqlibdoc.who.int/diabetes/publications/dia
gnosis-diabetes2006/en. Accessed 6 Mar 2021.
27. American Diabetes Association. Standards of medical care in diabetes.
Diabetes Care. 2014;37:S14–80.
28. John WG; UK Department of Health Advisory Committee on Diabetes. Use
of HbA1c in the diagnosis of diabetes mellitus in the UK. The
implementation of World Health Organization guidance 2011. Diabet Med.
2012;11:1350–7.
29. Tatsch E, Bochi GV, Piva SJ, Pereira RS, Kober H, De Carvalho JA, et al.
Hba(1c) as a tool for the diagnosis of type 2 diabetes: comparison with
fasting glucose. Clin Lab. 2012;58(3-4):347–50.
30. Gillison F, Stathi A, Reddy P, Perry R, Taylor G, Bennett P, et al. Processes of
behavior change and weight loss in a theory-based weight loss
intervention program: a test of the process model for lifestyle behavior
change. Int J Behav Nutr Phys Act. 2015;12:1–15.
31. Lindström J, Neumann A, Sheppard K, Gilis-Januszewska A, Greaves CJ,
Handke U, et al. Take action to prevent diabetes: a toolkit for the prevention
of type 2 diabetes in Europe. Hormone Metab Res. 2010;42:S37–55.
32. Kontopantelis E, Reeves D, Valderas JM, Campbell S, Doran T. Recorded
quality of primary care for patients with diabetes in England before and
after the introduction of a financial incentive scheme: a longitudinal
observational study. BMJ Qual Saf. 2013;22:53–64.
33. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling.
Diab Care. 2004;27:1487–95 Review.
34. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE,
et al. International physical activity questionnaire: 12-country reliability and
validity. Med Sci Sports Exerc. 2003;35:1381–95.
35. Booth M. Assessment of physical activity: an international perspective. Res Q
Exerc Sport. 2000;71(2 Suppl):S114–20.
36. Shannon J, Kristal AR, Curry SJ, Beresford SA. Application of a behavioral
approach to measuring dietary change: the fat- and fiber-related diet
behavior questionnaire. Cancer Epidemiol Biomarkers Prev. 1997;6:355–61.
37. Bradley C. The Well Being Questionnaire. In: Bradley C, editor. Handbook of
psychology and diabetes: a guide to psychological measurement in
diabetes research and practice. London: Harwood Academic Publishers;
1994
38. Brooks R. EuroQoL: the current state of play. Health Policy. 1996;37:53–72.
39. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The
development of an individualized questionnaire measure of perceived impact
of diabetes on quality of life: the ADDQoL. Qual Life Res. 1999;8:79–91.
40. The English Indices of Deprivation (2015) Statistical Release. Department for
Communities and Local Government https://www.gov.uk/government/sta
tistics/english-indices-of-deprivation-2015. Accessed 6 Mar 2021.
41. Bradley C, Speight J. Patient perceptions of diabetes and diabetes therapy:
assessing quality of life. Diab Metab Res Rev. 2002;18(Suppl 3):S64–9.
42. Bijl JV, Poelgeest-Eeltink AV, Shortridge-Baggett L. The psychometric
properties of the diabetes management self-efficacy scale for patients with
type 2 diabetes mellitus. J Adv Nurs. 1999;30:352–9.
43. Curtis L. Unit costs of health and social care 2017. The University of Kent:
Personal Social Services Research Unit; 2017.
44. Improvement NHS. National schedule of reference costs 2016-17. London:
Department of Health; 2017.
45. NHS Digital. Prescription cost analysis, England - 2017. London: Health and
Social Care Information Centre; 2017.
46. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based
cost-effectiveness analysis: the importance of controlling for baseline utility.
Health Econ. 2005;14:487–96.
47. Brooks R. EuroQol: the current state of play. Health policy. 1996;37:53-72.
National Institute for Health and Care Excellence. Guide to the methods of
technology appraisal 2013. Available from: https://www.nice.org.uk/process/
pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2
007975843781. Accessed 6 Mar 2021.
48. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in
cost-effectiveness analysis conducted within randomised controlled trials.
Pharmacoeconomics. 2014;32:1157–70.
49. Rubin DB. Inference and missing data. Biometrika. 1976;63:581–92.
50. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment
and subgroup analysis for non-censored cost-effectiveness data. Health
Econ. 2004;13:461–75.
51. Chatterjee S, Davies MJ, Heller S, Speight J, Snoek FJ, Khunti K. Diabetes
structured self-management education programmes: a narrative review and
current innovations. Lancet Diab Endocrinol. 2018;6:130–42.
52. Pillay J, Armstrong MJ, Butalia S, Donovan LE, Sigal RJ, Vandermeer B, et al.
Behavioral programs for type 2 diabetes mellitus: a systematic review and
network meta-analysis. Ann Intern Med. 2015;163:848–60.
53. Look AHEAD Research Group Weight change 2 years after termination of
the intensive lifestyle intervention in the Look AHEAD Study. Obesity (Silver
Spring). 2020; 28 : 893-901.
54. Harding AH, Sargeant LA, Welch A, Oakes S, Luben RN, Bingham S, et al. Fat
consumption and HbA(1c) levels: the EPIC-Norfolk study. Diabetes Care.
2001;24:1911–6.
55. Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P,
et al. Effects of intensive glucose control on microvascular outcomes in
patients with type 2 diabetes: a meta-analysis of individual participant
data from randomised controlled trials. Lancet Diab Endocrinol. 2017;
5(6):431–7.
56. Rozing MP, Møller A, Aabenhus R, Siersma V, Rasmussen K, Køster-
Rasmussen R. Changes in HbA1c during the first six years after the
diagnosis of type 2 diabetes mellitus predict long-term microvascular
outcomes. Plos One. 2019;14:e0225230. https://doi.org/10.1371/journal.pone.
0225230 PMID: 31774849.
57. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S,
Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering
treatment on all cause mortality, cardiovascular death, and microvascular
events in type 2 diabetes: meta-analysis of randomised controlled trials.
BMJ. 2011;343:d4169. https://doi.org/10.1136/bmj.d4169.
58. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al.
Intensive glycaemic control for patients with type 2 diabetes: systematic
review with meta-analysis and trial sequential analysis of randomised
clinical trials. BMJ. 2011;343:d6898. https://doi.org/10.1136/bmj.d6898.
59. Smith SM, Paul G, Kelly A, Whitford DL, O'Shea E, O'Dowd T. Peer support
for patients with type 2 diabetes: cluster randomised controlled trial. BMJ.
2011;342:d715. https://doi.org/10.1136/bmj.d715.
60. Simmons D, Prevost AT, Bunn C, Holman D, Parker RA, Cohn S, et al. Impact
of community based peer support in type 2 diabetes: a cluster randomised
controlled trial of individual and/or group approaches. Plos One. 2015;10(3):
e0120277. https://doi.org/10.1371/journal.pone.0120277.
61. Chan JC, Sui Y, Oldenburg B, Zhang Y, Chung HH, Goggins W, et al. Effects
of telephone-based peer support in patients with type 2 diabetes mellitus
receiving integrated care: a randomized clinical trial. JAMA Intern Med.
2014;174:972–81.
62. Pienaar M, Reid M. Self-management in face-to-face peer support for adults
with type 2 diabetes living in low- or middle-income countries: a systematic
review. BMC Public Health. 2020;20(1):1834. https://doi.org/10.1186/s12889-
020-09954-1.
63. McGowan P, Lynch S, Hensen F. The role and effectiveness of telephone
peer coaching for adult patients with type 2 diabetes. Can J Diab. 2019;43:
399–405.
64. Heisler M, Vijan S, Makki F, Piette JD. Diabetes control with reciprocal peer
support versus nurse care management: a randomised trial. Ann Intern
Med. 2010;153:507–15.
65. Moskowitz D, Thom DH, Hessler D, Ghorob A, Bodenheimer T. Peer
coaching to improve diabetes self-management: which patients benefit
most? J Gen Intern Med. 2013;28:938–42.
66. Rogers EA, Hessler DM, Bodenheimer TS, Ghorob A, Vittinghoff E, Thom DH.
Diabetes peer coaching: do “better patients” make better coaches? Diabetes
Educ. 2014;40:107–15.
67. Afshar R, Tang TS, Askari AS, Sidhu R, Brown H, Sherifali D. Peer support
interventions in type 2 diabetes: review of components and process
outcomes. J Diabetes. 2020;12:315–8.
68. Bandura, A Analysis of modelling processes. 1975; School Psychology
Review, Volume 4, Issue 1
69. Schulz BR, McDonald M J. Weight loss self-efficacy and modelled behaviour:
gaining competence through example. Canadian Journal of Counselling
and Psychotherapy 1010; 45(1). Retrieved from https://cjc-rcc.ucalgary.ca/a
rticle/view/59204. Accessed 6 Mar 2021.
70. Farmer AJ, Rodgers LR, Lonergan M, Shields B, Weedon MN, Donnelly L.
Adherence to oral glucose-lowering therapies and associations with 1-year
HbA1c: a retrospective cohort analysis in a large primary care database.
Diab Care. 2016;39:258–63.
Sampson et al. BMC Medicine          (2021) 19:183 Page 16 of 17
71. Tang Y, Weiss T, Liu J, Rajpathak S, Khunti K. Metformin adherence and
discontinuation among patients with type 2 diabetes: a retrospective cohort
study. J Clin Transl Endocrinol. 2020;20:100225.
72. Nichols GA, Rosales AG, Kimes TM, Tunceli K, Kurtyka K, Mavros P. The
change in HbA1c associated with initial adherence and subsequent change
in adherence among diabetes patients newly initiating metformin therapy. J
Diab Res. 2016;2016:9687815. https://doi.org/10.1155/2016/9687815.
73. Thom DH, Ghorob A, Hessler D, De Vore D, Chen E, Bodenheimer TA.
Impact of peer health coaching on glycemic control in low-income patients
with diabetes: a randomized controlled trial. Ann Fam Med. 2013;11:137–44.
74. Newman PM, Franke MF, Arrieta J, Carrasco H, Elliott P, Flores H, et al.
Community health workers improve disease control and medication
adherence among patients with diabetes and/or hypertension in Chiapas,
Mexico: an observational stepped- wedge study. BMJ Global Health. 2018;
3(1):e000566.
75. Shiyanbola OO, Kaiser BL, Thomas GR, Tarfa A. Preliminary engagement of a
patient advisory board of African American community members with type
2 diabetes in a peer-led medication adherence intervention. Res Involv
Engagem. 2021;7(1):4. https://doi.org/10.1186/s40900-020-00245-y.
76. Kaselitz E, Shah M, Choi H, Heisler M. Peer characteristics associated with
improved glycemic control in a randomized controlled trial of a reciprocal
peer support program for diabetes. Chronic Illn. 2019;15:149–56.
77. Mizokami-Stout K, Choi H, Richardson CR, Piatt G, Heisler M. Diabetes
distress and glycemic control in type 2 diabetes: mediator and moderator
analysis of a peer support intervention. JMIR Diab. 2021;6(1):e21400. https://
doi.org/10.2196/21400.
78. Feldman AL, Griffin SJ, Fhärm E, Norberg M, Wennberg P, Weinehall L, et al.
Screening for type 2 diabetes: do screen-detected cases fare better?
Diabetologia. 2017;60(11):2200–9.
79. Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S, et al.
Effectiveness of the diabetes education and self management for ongoing
and newly diagnosed (DESMOND) programme for people with newly
diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ. 2008;
336(7642):491–5.
80. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al.
Durability of a primary care-led weight-management intervention for
remission of type 2 diabetes: 2-year results of the DiRECT open-label,
cluster-randomised trial. Lancet Diab Endocrinol. 2019;7:344–55.
81. Taheri S, Zaghloul H, Chagoury O, Elhadad S, Ahmed SH. El Khatib N Effect
of intensive lifestyle intervention on bodyweight and glycaemia in early
type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised
controlled trial. Lancet Diab Endocrinol. 2020;8:477–89.
82. Frost J, Wingham J, Britten N, Greaves C, Abraham C, Warren FC, et al.
Home-based rehabilitation for heart failure with reduced ejection fraction:
mixed methods process evaluation of the REACH-HF multicentre
randomised controlled trial. BMJ Open. 2019. https://doi.org/10.1136/
bmjopen-2018-026039.
83. Husk K, Elston J, Callaghan L, Asthana S. Social prescribing: where is the
evidence. Br J Gen Pract. 2019;69(678):6–7.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Sampson et al. BMC Medicine          (2021) 19:183 Page 17 of 17
